Tyson Crystal C, Coffman Thomas M
Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Nephron. 2017;135(4):287-290. doi: 10.1159/000455130. Epub 2017 Feb 4.
Systolic Blood Pressure Intervention Trial (SPRINT) was a multicenter randomized controlled trial showing the significant benefit of intensive reduction of blood pressure to a target of 120 mm Hg in individuals with hypertension and elevated cardiovascular risk. Because SPRINT includes the largest cohort of adults with chronic kidney disease (CKD) to be prospectively studied in a hypertension intervention trial, it has particular relevance to the field of nephrology. Here, we review the findings of SPRINT and assess their potential impact on guidelines for treatment of hypertension in patients with CKD. We believe that the data from SPRINT will support a recommendation for lowering blood pressure targets to 120 mm Hg in a substantial segment of adults with CKD.
收缩压干预试验（SPRINT）是一项多中心随机对照试验，该试验表明，对于患有高血压且心血管风险升高的个体，将血压强化降低至120 mmHg的目标具有显著益处。由于SPRINT纳入了高血压干预试验中前瞻性研究的最大慢性肾脏病（CKD）成年人群体，因此它与肾脏病领域具有特别的相关性。在此，我们回顾了SPRINT的研究结果，并评估其对CKD患者高血压治疗指南的潜在影响。我们认为，SPRINT的数据将支持在相当一部分CKD成年患者中将血压目标降低至120 mmHg的建议。
